Onconetix, Inc. (NasdaqCM: ONCO)
Health Care · Biotechnology · US
$0.64
-1.46% today · -99.6% 1Y
Onconetix, Inc. (NasdaqCM: ONCO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.57M and employs 2 people.
Over the last twelve months the share price has lost 99.6%, trading between 0.62 and 209.50.
Tweenvest scores Onconetix, Inc. across four factors: quality 23/100, value 47/100. Its strongest factor is value.
ONCO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.57M
- Revenue (TTM)
- $645.82K
- P/E
- —
- EPS
- -17.16
- Dividend yield
- —
- Beta (5Y)
- 2.69
- 52-week high
- $209.50
- 52-week low
- $0.62
- Avg volume (3M)
- —
- Shares outstanding
- 3.95M
- Employees
- 2
- Next earnings
- —
About Onconetix, Inc.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
- ISIN
- US68237Q4010
- Founded
- 2018
- Listed since
- Feb 18, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.